Author:
Yoon Suhyeon,Noh Hyuna,Jin Heejin,Lee Sungyoung,Han Soyul,Kim Sung-Hee,Kim Jiseon,Seo Jung Seon,Kim Jeong Jin,Park In Ho,Oh Jooyeon,Bae Joon-Yong,Lee Gee Eun,Woo Sun-Je,Seo Sun-Min,Kim Na-Won,Lee Youn Woo,Jang Hui Jeong,Hong Seung-Min,An Se-Hee,Lyoo Kwang-Soo,Yeom Minjoo,Lee Hanbyeul,Jung Bud,Yoon Sun-Woo,Kang Jung-Ah,Seok Sang-Hyuk,Lee Yu Jin,Kim Seo Yeon,Kim Young Been,Hwang Ji-Yeon,On Dain,Lim Soo-Yeon,Kim Sol Pin,Jang Ji Yun,Lee Ho,Kim Kyoungmi,Lee Hyo-Jung,Kim Hong Bin,Park Jun Won,Jeong Dae Gwin,Song Daesub,Choi Kang-Seuk,Lee Ho-Young,Choi Yang-Kyu,Choi Jung-ah,Song Manki,Park Man-Seong,Seo Jun-Young,Nam Ki Taek,Shin Jeon-Soo,Won Sungho,Yun Jun-Won,Seong Je Kyung
Abstract
Abstract
Background
As the number of large-scale studies involving multiple organizations producing data has steadily increased, an integrated system for a common interoperable format is needed. In response to the coronavirus disease 2019 (COVID-19) pandemic, a number of global efforts are underway to develop vaccines and therapeutics. We are therefore observing an explosion in the proliferation of COVID-19 data, and interoperability is highly requested in multiple institutions participating simultaneously in COVID-19 pandemic research.
Results
In this study, a laboratory information management system (LIMS) approach has been adopted to systemically manage various COVID-19 non-clinical trial data, including mortality, clinical signs, body weight, body temperature, organ weights, viral titer (viral replication and viral RNA), and multiorgan histopathology, from multiple institutions based on a web interface. The main aim of the implemented system is to integrate, standardize, and organize data collected from laboratories in multiple institutes for COVID-19 non-clinical efficacy testings. Six animal biosafety level 3 institutions proved the feasibility of our system. Substantial benefits were shown by maximizing collaborative high-quality non-clinical research.
Conclusions
This LIMS platform can be used for future outbreaks, leading to accelerated medical product development through the systematic management of extensive data from non-clinical animal studies.
Funder
National research foundation of Korea
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Kahn N. New virus discovered by Chinese scientists investigating pneumonia outbreak. The Wall Street Journal. 2020. https://www.wsj.com/articles/new-virus-discovered-by-chinese-scientists-investigating-pneumonia-outbreak-11578485668. Accessed 27 May 2022.
2. Morens DM, Daszak P, Taubenberger JK. Escaping Pandora’s box—another novel coronavirus. N Engl J Med. 2020;382(14):1293–5.
3. James M, Marguerite L, Tomasz Z, James B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–36.
4. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.e8.
5. Wu R, Wang L, Kuo HD, Shannar A, Peter R, Chou PJ, et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. 2020;6(3):56–70.